Ikeda Tetsusuke, Hotta Tomomitsu
Dept. of Hematology, Oncology and Rheumatology, Tokai University School of Medicine, Boseidai Isehara city, Kanagawa 259-1193, Japan.
Gan To Kagaku Ryoho. 2005 Jan;32(1):6-10.
The choice of second-line chemotherapy for malignant lymphoma in cases of both Hodgkin lymphoma and non-Hodgkin lymphoma depends on the results of first-line therapies. However, the trends in first-line therapy for malignant lymphoma have undergone significant changes over the last few years. The change has resulted from three facts: 1) the concept of dose intensity had to be revised, 2) newly-found prognostic factors have shown the need for therapy that takes risk grouping into consideration, and 3) new therapies, such as immunotherapy using monoclonal antibodies, have emerged. Based on these recent trends, this paper describes salvage therapies as a "recommendation" or "guideline" for cases of relapse or therapy-resistant disease which involve standard therapeutic measures.
霍奇金淋巴瘤和非霍奇金淋巴瘤患者恶性淋巴瘤二线化疗方案的选择取决于一线治疗的结果。然而，在过去几年中，恶性淋巴瘤一线治疗的趋势发生了显著变化。这种变化源于三个事实：1）剂量强度的概念必须修订；2）新发现的预后因素表明需要考虑风险分组的治疗方法；3）新的治疗方法，如使用单克隆抗体的免疫疗法已经出现。基于这些最新趋势，本文将挽救性治疗描述为针对复发或治疗抵抗性疾病病例的“推荐”或“指南”，其中涉及标准治疗措施。
